Skip to main content

Posts

Showing posts with the label Pharma
Pharmaceutical sector was mostly upper limit on Friday.

Searle Reported Loss in Q3 2024, Revenue Down but Gross margin slightly Up

SEARL | The Searle Company Limited Earning Release Q3-Mar 2024 Latest Announcement For the quarter ending March 2024, SEARL reported a loss after tax of Rs. 110 million. The loss per share came out at Rs. 0.21. SEARL did not announce any cash dividends along with the results announcement.  Moreover, it is worth noting that SEARL has declared no cash dividends in the last four quarters. On a 9-month basis, SEARL announced a PAT of Rs. 111 million, compared to a PAT of Rs. 639 million in the same period last year. To provide historical context to the earnings, note that on a twelve-month trailing basis, SEARL has recorded a loss after tax of Rs. 226.0 million, compared to a loss after tax of Rs. 19.16 million last year. Profit and Loss Analysis To better comprehend changes in profit and loss in this quarter over last year , note that revenue decreased by 5.7% in this quarter, compared to last year, and the gross profit margin increased to 49% from 46% last year, resulting in a 0.6% i...

Good news for Pakistan's Pharma Sector Investors!

Court ruling allows drug makers to set their own prices Most of the Pharma Sector stocks were at upper limit today as PSX continued in bullish momentum and cross 68k level. The Lahore High Court has lifted a stay order on deregulating drug prices, giving pharmaceutical companies more control over pricing. This is a positive development for the industry, which has been struggling with low profitability due to high inflation and currency devaluation. Previously, companies could only raise prices for non-essential drugs by a set amount each year. Now, they will be able to adjust prices based on their costs. This is expected to lead to improved profitability and potentially new product launches in the sector. recall that; The government had approved deregulation of non-essential drug prices in February 2024. However, a court order put a temporary hold on the decision. Under the 2018 pricing policy, drug prices were linked to inflation, but companies faced limitations on how much they could...